Introduction 23
Cancer is an evolutionary system that results from the accumulation of somatic mutations 24
(1), resulting in cells that increase their fitness and divide faster, die less frequently, and 25 no longer follow the rules dictated by their environments. New mutations in individual 26 cells within a neoplasm can create subclones of genetically identical cells all sharing the 27 same common ancestor, and these subclones then compete with each other for limited 28 resources. Cancer cells are an evolving population of asexually-reproducing cells, and the 29 rate and dynamics of adaptation in asexually-evolving populations have been studied 30 experimentally and theoretically in evolutionary biology (reviewed in (2) ). 31 
32
A fundamental goal of research into carcinogenesis, with implications for cancer 33 prevention, is to determine the order of mutations that occur in a neoplasm as it 34
progresses from normal tissue to cancer. This has been explored in various cancer types, 35 including breast cancer (3), lung cancer (4), and melanoma (5) . In a canonical paper (6) , 36 the order of mutations for colorectal cancer was reconstructed from 172 colorectal tumor 37 specimens (7). The specimens were classified according to tumor size and grade, and a 38 small set of genetic alterations was characterized in these same samples. The order of 39 mutations leading to colon cancer was constructed from these data by identifying the 40 mutations whose frequency across tumors increased in conjunction with increases in the 41 tumor size and grade (6) . This analysis has been widely influential and used as a model 42 for other cancer systems (4, 8, 9) . Even at its conception, this model was not meant to (Table S5) . With high mutation rates, this often led to 90 competition between clones of with similar fitness because multiple sub-clones evolved 91 before any one sub-clone expanded to fill the crypt. The effect of most of the mutations 92 on the phenotypes increases the fitness of a clone by allowing it to grow faster, divide 93 less frequently, or self-renew. In principle, these phenotypes could be conferred through a 94 variety of genetic alterations in the pathways that determine the phenotypes, but we do 95 not model the pathways explicitly. By focusing on phenotypically related sets of genes, 96
we have expanded the focus of this model from genes to sets of genes, similar to the 97 expansion of cancer genes to cancer pathways (reviewed in (18) ), without making a 98 commitment to the particular genetic structure of the phenotypes. We assume that a 99 mutation for each phenotype has an equal chance of occurring because the genotype-100 phenotype map is not well characterized. When a new mutation affecting a phenotype 101 occurs in a cell, we assume that each mutation occurs at a different locus in one of the of 102 genes responsible for the phenotype, in the spirit of the infinite alleles model (19) . For 103 each simulation, we recorded detailed information on mutations, cell lineages, and 104 population size and composition over time. 105
106
All cells in the model were initially wild-type cells with no mutant phenotypes as in a 107 normal crypt; they were then allowed to divide, mutate, differentiate, and die. (Table S3 ). Due to computational restrictions, our simulations were conducted 116 in the realm of population sizes smaller than detectable clinically. However, when we 117 varied the maximum possible size of the neoplasm, and thus the detection size of the 118 tumor, there was little effect on the mean size of the largest clone or the heterogeneity. 119
Thus, the conclusions we draw from smaller tumor sizes apply to larger tumor sizes. 120
Accumulation of mutant phenotypes in a cell was low enough that cancer was a relatively 121 rare event. Of the 10,002 simulations, 90 (0.9%) terminated in cancer and 4,639 (46.4%) 122 were benign polyps. 123
124

Inferring the path model from cross-sectional data 125
In our analysis of the simulation data, we made the following assumptions: a tumor was 126 detected as soon as it reached some size, a biopsy was taken immediately upon detection, 127 and a mutation could be detected once it comprised 50% of the cells. We biopsied 128 neoplasms at detection sizes ranging from 700 cells to 10,000 cells (the mean size of wild 129 type cell populations were 772 cells, s.e.m. 7), and obtained the "genotype" for each 130 biopsy (mutant phenotype status; see Fig. 2A biopsies having a particular mutation in a phenotype for each size threshold. This was 133 used to identify the order in which the majority of tumors (> 50%) at a given size had a 134 mutant allele. If multiple phenotypes reached 50% at the same size threshold, the mutant 135 phenotype occurring in more of the biopsies was given precedence. Mutant phenotypes 136 that did not occur in 50% of the samples in the final size biopsies were ordered by the 137 percent of biopsies in which they occurred. For example, neither self-sufficiency in 138 growth signals nor insensitivity to antigrowth signal mutations reached majority in 50% 139 of the tumors, but self-sufficiency in growth signals was found in more biopsies and so 140 we concluded that it occurred before insensitivity to antigrowth signals. We sampled 5 or 10 cells for every tumor analyzed. Because we recorded the exact cell 160 lineage relationship between all the clones in every tumor, we were able to obtain the 161 exact cell lineage relationship between the sampled cells as in Fig. 2C . In our analyses, 162
we assume perfect information and do not simulate experimental noise in either the cross-163 sectional or the cell lineage analyses. We assume that by assaying single crypts (21) , 164 cloning single cells (22) 
Results
172
To test if the temporal order and the order reconstructed from cross-sectional data are 173 consistent, we need detailed data on the mutational order and timing for every clone in 174 neoplasms that progress to cancer. It is difficult to obtain the data to do this 175 experimentally. Thus, we constructed an agent-based model of cell evolution, in which 176
Cancer Research. First, we characterized the simulated neoplasms that progressed to cancer. We found that 188 the necessary and sufficient mutant phenotypes for progression to cancer were loss of 189 differentiation, evasion of apoptosis, and sustained angiogenesis ( For the subsequent mutations, there is at best a weak tendency for one mutation to occur 209 as opposed to another (Fig. S2) . 210
211
Next, we repeated the experiments to obtain the cross-sectional order of mutations, as 212 was done in colon cancer (6), using our data. First, we obtained the mutational state of 213 the simulated neoplasms at increasing tumor grades that we approximated by the 214 neoplasm size, defined as the number of cells comprising a neoplasm. To do so, we 215 biopsied neoplasms that progressed to cancer as they crossed various size thresholds and 216 genotyped them for the presence of mutant alleles in the majority of cells. The frequency-217 based ordering of mutations inferred from this analysis was loss of differentiation, 218 evasion of apoptosis, limitless replicative potential, sustained angiogenesis, genomic 219 instability, self-sufficiency in growth signals, and insensitivity to antigrowth signals ( 
4A and B). 221 222
In order to quantify how well the temporal order matched the path order, we determined 223 the percentage of tumor cells when cancer was detected whose evolutionary order over 224 time matched the path order obtained from cross-sectional data. We found that most 225 simulations had few cells in their tumors with consistent temporal and cross-sectional 226 path orders (mean 7.3%, s.e.m. 1.0%; Fig. 4C ). In fact, 41% of tumors had no cells with 227 consistent orders and 68% had at most 1% of cells with consistent order. Thus, we saw 228 that the order inferred from cross-sectional data was inconsistent with the temporal order 229 of mutations for most cells. This is true across a range of parameter, or fitness, values for 230 the cancer phenotypes, including telomere length, neoplasm size, mutation rate, and the 231 probability of cell division. The sensitivity analyses are summarized in Table S3 . 232 233 Then, we examined whether cells' temporal orders were consistent with the order 234 reconstructed from an oncogenetic tree model. We obtained the oncogenetic branching 235 tree model from our cross-sectional cancer data (Fig. S3 ) and compared it to the temporal 236 order from individual cells in cancers. We found that more temporal paths were 237 consistent with the oncogenetic tree models than the simple path model, but most tumors 238 still had relatively low fractions of temporal paths consistent with the oncogenetic tree 239 oncogenetic tree order; 54% of tumors have more than 1% of cells with consistent 243 temporal orders. Like path models, these models do not fully specify the mutational 244 spectrum observed in experimental cross-sectional studies of neoplasms. In one study in 245 colon cancer, 11% of the neoplasms had combinations of mutations that were 246 inconsistent with the oncogenetic tree identified (16) . Of course, characteristics of 247 neoplasms like mutation rate, number of cells, cell motility, and the relative fitness of 248 new mutations affects the probability that a clone can reach fixation. In turn, this affects 249 the percent of clones with consistent temporal and cross-sectional mutational orders. 250
251
We have shown that using cross-sectional methods to infer temporal order within tumors 252 is often misleading. Now, we address whether using intra-tumor data to reconstruct the 253 cell lineage, or genealogy of mutations, within individual tumors can better reflect the 254 temporal order. To do so, we used a genetic-dependency analysis on a subsample of cells 255 found in each final neoplasm. We sampled 5 cells per neoplasm and used these to 256 reconstruct a cell lineage for each cancer as in Fig. 2C . We compared the temporal 257 ordering of cells in the tumor at cancer to the same tumor's genealogy and found that 258 they were highly consistent ( Fig. 4D; (32, 33) and model systems (34) 
Discussion 274
We have used our agent-based model to simulate neoplastic progression. This approach 275 allowed us to record the cell lineage and population structure of neoplasms that 276 progressed to cancer. We have shown that using cross-sectional data to infer the 277 temporal order of mutations for all cells in a neoplasm rarely works; 41% of tumors had 278 no clones with consistent temporal and cross-sectional orders. These results are robust 279 and don't depend on exactly how any one hallmark is implemented. Some of this 280 mismatch between cross-sectional models and temporal orders can be due genetic 281 instability and low clonal expansion rates within tumors. This prevents selective sweeps 282 from reaching fixation, and thus neoplasms do not progress through discrete, interference, and the heterogeneity that accompanies it, can occur when mutation rates 308 are high but the fitness effects of new mutations are small. Another condition generating 309 exceptionally high intra-tumor heterogeneity occurs when mutation rates are high and 310 there is geographical isolation of subpopulations of cells. It is currently unknown which 311 of these clonal evolution dynamics are found in real tumors, though there is evidence for 312 high mutation rates and small fitness effects in colon cancer (38) , and evidence for small 313 fitness effects in pancreatic cancer and glioblastoma multiforme (39) . We observed 314 dynamics consistent with both clonal evolution and clonal interference in our simulations, 315 even within the same neoplasm (Fig. 5C ). For example, we observed that heterogeneity 316 decreased when a clone that acquired the loss of differentiation mutation fixed in the 317 population, as might occur during a clonal selective sweep (Fig. 5B) . Subsequently, 318 heterogeneity increased as clonal interference dominated the rest of the neoplastic 319 dynamics. In general, heterogeneity increased over the course of progression in the 320 simulations, with occasional drops that were immediately followed by increases. Thus, 321 one of the explanations for the low percent of clones within a tumor with matching 322 temporal and path orders is that there is not a single evolutionary path for tumor. Instead, 323 there are many clones, each of which can independently acquire genetic alterations as has 324 been suggested in Barrett's esophagus (21) . clone or if it fails to stabilize its telomeres. We observed both events (Fig. 5) . For 330 example, we observed a clone that acquired the insensitivity to antigrowth signals 331 mutation early on which allowed the clone to expand to a detectable size. Then, a loss of 332 differentiation mutation occurred independently in a wild-type cell. This new clone 333 quickly expanded and drove the original clone extinct. Later in progression of this same 334 neoplasm, a large clone eventually went extinct due to failure to stabilize its telomeres. 335
336
There is a further problem specifically with the construction of path models. Building 337 path models requires the characterization of several different neoplasms at different 338 stages. The stages are then ordered according to increasing size and grade, which is 339 assumed to correspond to a single, linear order of changes during progression to cancer. 340 This is how the in the path model in Fig. 4 was constructed. It may be an obvious point, 341
but by basing the path model on mutations associated with increasing size and grade, we 342 are identifying those mutations involved in increasing the neoplasm's size and grade. 343
That these mutations are involved in progression to cancer is an assumption (40) . Thus, 344 if histological grading does not reflect the necessary temporal sequence during 345 progression, then studies based on that ordering will of course be invalid (41) . than path models because they do not impose a strict order on every mutation in a tumor. 357
They also relax the assumption that the mutations that lead to neoplasms of increasing 358 size and grade are the same mutations that lead to cancer. However, we have shown that 359 even the oncogenetic tree order of mutations does not match the true evolutionary path. 360
Oncogenetic tree models have already been extended. Distance-based methods have also 361 been used to reconstruct oncogenetic tree models (43) and conjunctive Bayesian network 362 models have used directed acyclic graphs to represent mutation ordering (44) and have 363 been applied to cross-sectional data (45) . These models still suffer from the weakness of 364 cross-sectional data. Recently, a computational approach was developed to identify the 365 most likely paths through a mutational network for colorectal cancer and glioblastoma 366 using cross-sectional data; the authors found that not all evolutionary paths are accounted 367 for in the mutational networks, perhaps due to heterogeneity of temporal orders within 368 cancer types (46) . 
infer the temporal order of events is the assumption that the state of one tumor is 374 informative for the history of a tumor in a different patient. Both our model and recent 375 cancer resequencing efforts (30, 47, 48) show that there are likely many possible 376 evolutionary paths to cancer, not just between types of cancers, but even within a given 377 type of cancer. Each tumor is a unique evolutionary trajectory with occasional necessary 378 and sufficient phenotypic mutations that can be acquired differently in different tissues. 379
Further, tumors are populations of heterogeneous clones, each of which is evolving along 380 a distinct path. Thus, identifying a single path or oncogenetic tree of mutational events is 381 insufficient to describe this process. Reconstructing cell lineages within individual 382 tumors should reveal the true temporal order of events for the different clones within a 383 tumor (49) . 384
385
Because cancer is an evolutionary process (50), we can use some of the powerful tools of 386 evolutionary analyses to reveal the dynamics of cancer. We have shown that an 387 evolutionary analysis applied to intra-tumor samples can overcome the limitations of 388 cross-sectional analyses,. This can also resolve the conflicting results arising from 389 analyses using cross-sectional data (10). Finally, evolutionary tools can help to reveal the 390 dynamics of intra-tumor genetic heterogeneity that drives the process of tumor 391 progression and therapeutic resistance. Tables   Table 1. Hallmarks of cancer phenotypes and their effects on the model when mutated.
Grant Support
Phenotype
Model Effect Insensitivity to antigrowth signals Cells with this mutation have an increased probability for cell division Self-sufficiency in growth signals Cells with this mutation have an increased probability for cell division Evasion of apoptosis Cells with this mutation have a decreased probability of apoptosis Limitless replicative potential Mutation eliminates telomere loss during cell division. Cells with this mutation can divide more times than those without. Sustained angiogenesis Cells with this mutation increase the number of cells that can survive in a tumor.
Loss of differentiation
Cells with this mutation no longer differentiate at cell division. Genome instability Cells with this mutation have increased chances to acquire a new mutation. 
Figure Legends
